Abstract:Abstract The heterogeneity of fibroblasts in the murine and human lung during homeostasis and disease is increasingly recognized. It remains unclear if the different phenotypes identified to date are characteristic of unique subpopulations with unique progenitors or whether they arise by a process of differentiation from common precursors. Our understanding of this ubiquitous cell type is limited by an absence of well validated, specific, markers with which to identify each cell type and a clear consensus on the distinct populations present in the lung. Here we describe single cell RNA sequencing (scRNA-seq) analysis on mesenchymal cells from the murine lung throughout embryonic (E) development (E9.5 – 17.5), at post-natal day (P1 – 15), as well as in the adult and the aged murine lungs before and after bleomycin-induced fibrosis. We carried out complementary scRNA-seq on human lung tissue from a P1 lung, a month 21 lung and lung tissue from healthy donors and patients with idiopathic pulmonary fibrosis (IPF). The murine and human data were supplemented with publicly available scRNA-seq datasets. We consistently identified lipofibroblasts, myofibroblasts, pericytes, mesothelial cells and smooth muscle cells. In addition, we identified a novel population delineated by Ebf1 (early B-cell factor 1) expression and an intermediate subtype. Comparative analysis with human mesenchymal cells revealed homologous mesenchymal subpopulations with remarkably conserved transcriptomic signatures. Comparative analysis of changes in gene expression in the fibroblast subpopulations from age matched non-fibrotic and fibrotic lungs in the mouse and human demonstrates that many of these subsets contribute to matrix gene expression in fibrotic conditions. Subtype selective transcription factors were identified and putative divergence of the clusters during development were delineated. Prospective isolation of these fibroblast subpopulations, localization of signature gene markers, and lineage-tracing each cluster are under way in the laboratory. This analysis will enhance our understanding of fibroblast heterogeneity in homeostasis and fibrotic disease conditions.

Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?

Emerging Roles of Fibroblasts in Cardiovascular Calcification

Identifying Characteristics of Dermal Fibroblasts in Skin Homeostasis and Disease

Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics

Markers of Dermal Fibroblast Subpopulations for Viable Cell Isolation via Cell Sorting: A Comprehensive Review

Improved Dermal Regeneration Using a Combination of Dermal Substitutes and Dermal Fibroblast Optimization: A Hypothesis.

Understanding Fibroblast Heterogeneity in Form and Function

P17 Dissection of the molecular and cellular heterogeneity of dermal fibroblasts in skin fibrosis

Single-cell RNA-seq Reveals Fibroblast Heterogeneity and Increased Mesenchymal Fibroblasts in Human Fibrotic Skin Diseases

Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis

Fibroblasts: Heterogeneous Cells With Potential in Regenerative Therapy for Scarless Wound Healing

Targeting Fibrosis: Mechanisms and Clinical Trials

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation

The role of dermal fibroblasts in autoimmune skin diseases

Diversity of fibroblasts--a review on implications for skin tissue engineering

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Recent Advances in Single-Cell Profiling and Multispecific Therapeutics: Paving the Way for a New Era of Precision Medicine Targeting Cardiac Fibroblasts

Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases

Definition and Signatures of Lung Fibroblast Populations in Development and Fibrosis in Mice and Men

Targeting fibrosis, mechanisms and cilinical trials